Product Introduction:
Dyrade‑M DS combines metronidazole (400 mg) and diloxanide furoate (500 mg) in a dual-action formulation. Metronidazole targets tissue-invading protozoa and bacteria, while diloxanide furoate acts within the intestinal lumen to eliminate cyst-stage parasites, effectively treating both active and carrier stages of amoebiasis.
Uses:
-
Treats acute intestinal amoebiasis and amoebic dysentery
-
Eliminates both invasive and cystic stages of Entamoeba histolytica
-
Helps relieve symptoms such as abdominal cramps, diarrhea, and nausea
-
Reduces fatigue and dehydration following infection
Benefits:
-
Dual-stage infection clearance in a single tablet
-
Rapid symptomatic relief, often within 48–72 hours
-
Simplifies treatment with a single combination tablet
-
Improves patient adherence due to twice-daily dosing
Composition:
-
Metronidazole – 400 mg
-
Diloxanide Furoate – 500 mg
-
Inactive excipients for tablet formation
Side Effects:
-
Common: metallic taste, mild nausea, dry mouth, stomach discomfort
-
Possible: headache, dizziness, mild skin rash in sensitive individuals
-
Rare but serious: seizures (with predisposition), optic neuritis, peripheral neuropathy
Safety Advice:
-
Adults: Take 1 tablet twice daily after meals for 5–10 days, or as directed
-
Swallow with water; taking with food helps minimize stomach upset
-
Avoid alcohol during and for 72 hours after treatment—may cause adverse reactions
-
Not recommended for children unless specifically instructed by a doctor
-
Use cautiously in patients with liver or central nervous system disorders
-
Monitor for neurological symptoms like numbness or seizures
-
Complete the full course even if symptoms resolve early to prevent recurrence
-
Store in a cool, dry place below 25 °C, away from sunlight
-
Keep out of reach of children
